Dilazep is a vasodilator that acts as an adenosine reuptake inhibitor.[1][2]

It is used for the treatment of cardiopathy and renal disorders.[3]

Synthesis

Thieme Patent:[4] Prec (page 935):[5]

The reaction of bis-(3-hydroxypropyl)-ethylene diamine (1) with 1-Bromo-3-chloropropane (2) gives homopiperazine [19970-80-0] (3). Esterification by reaction with 3,4,5-Trimethoxybenzoyl Chloride [4521-61-3] (4) completed the synthesis of Dilazep (5).

See also

References

  1. ^ Deguchi H, Takeya H, Wada H, Gabazza EC, Hayashi N, Urano H, Suzuki K (September 1997). "Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes". Blood. 90 (6): 2345–56. doi:10.1182/blood.V90.6.2345. PMID 9310485.
  2. ^ PubChem. "Dilazep". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-08-18.
  3. ^ "Pharmaceuticals". Kowa Company Ltd.
  4. ^ GB1107470 idem Herbert Arnold, Kurt Pahls, Rolf Rebling,Norbert Brock, Hans-Dieter Lenke, U.S. patent 3,532,685 (1970 to Asta Werke Ag Chem Fab).
  5. ^ Schlögl, K., Schlögl, R. (1964). "Über pharmakodynamisch wirksame 3,4,5-Trimethoxybenzoate und verwandte Ester von symmetrischen Bis-hydroxyalkylpiperazinen und-dialkylpolymethylendiaminen". Monatshefte für Chemie. 95 (3): 922–941. doi:10.1007/BF00908805.